Novavax Cut Its Outlook Despite Beating Third-Quarter Forecasts. Is It A Sell?
Things were looking up for Novavax stock after the FDA resolved a clinical hold. But the company trimmed its outlook. Is NVAX stock a sell?
Advertisement
Some parts of this page are not supported on your current browser version. Please upgrade to a recent browser version.
Things were looking up for Novavax stock after the FDA resolved a clinical hold. But the company trimmed its outlook. Is NVAX stock a sell?